Li, T.; Xu, Y.; Sun, W.; Yan, W.; Wang, C.; Hu, T.; Zhang, X.; Luo, Z.; Liu, X.; Chen, Y.
Adjuvant Anti-PD-1 Immunotherapy versus Conventional Therapy for Stage III Melanoma: A Real-World Retrospective Cohort Study. Pharmaceuticals 2023, 16, 41.
https://doi.org/10.3390/ph16010041
AMA Style
Li T, Xu Y, Sun W, Yan W, Wang C, Hu T, Zhang X, Luo Z, Liu X, Chen Y.
Adjuvant Anti-PD-1 Immunotherapy versus Conventional Therapy for Stage III Melanoma: A Real-World Retrospective Cohort Study. Pharmaceuticals. 2023; 16(1):41.
https://doi.org/10.3390/ph16010041
Chicago/Turabian Style
Li, Tong, Yu Xu, Wei Sun, Wangjun Yan, Chunmeng Wang, Tu Hu, Xiaowei Zhang, Zhiguo Luo, Xin Liu, and Yong Chen.
2023. "Adjuvant Anti-PD-1 Immunotherapy versus Conventional Therapy for Stage III Melanoma: A Real-World Retrospective Cohort Study" Pharmaceuticals 16, no. 1: 41.
https://doi.org/10.3390/ph16010041
APA Style
Li, T., Xu, Y., Sun, W., Yan, W., Wang, C., Hu, T., Zhang, X., Luo, Z., Liu, X., & Chen, Y.
(2023). Adjuvant Anti-PD-1 Immunotherapy versus Conventional Therapy for Stage III Melanoma: A Real-World Retrospective Cohort Study. Pharmaceuticals, 16(1), 41.
https://doi.org/10.3390/ph16010041